BEND, Ore.--(BUSINESS WIRE)--Agere Pharmaceuticals, Inc., a leading CDMO and innovator in oral bioavailability solutions announced today that R. Brendt Stallings has joined the company's board of directors. Mr. Stallings is an executive vice president at DoubleLine Capital, LLP, and a founding partner at DoubleLine Equity LP. He was formerly group managing director, senior portfolio manager at Trust Company of the West (TCW), where he most recently co-directed the TCW Small- and Mid-Cap Growth Equities team.
By adding Brendt's expertise in financial management, our company is well poised to expand while ensuring financial stability, which is a critical aspect in meeting the increasing needs of our worldwide client base.
Brendt brings significant experience in a director role in general, and in helping companies mitigate risk, commented Ron Rohrer, Agere's chairman. As Agere enters the next chapter of rapid growth toward the small-cap company range, Brendt's expertise will prove invaluable.
Small-cap companies fall into the range of a market capitalization of between $300 million to $2 billion. Agere is a privately-funded company, and has experienced an average of 40% revenue growth per year since 2011, with a 50% growth rate between 2012 and 2013.
Agere currently has strong scientific and engineering leadership and depth, and also extensive experience in growing start-up companies, commented Marshall Crew, Agere co-founder and president and CEO. By adding Brendt's expertise in financial management, our company is well poised to expand while ensuring financial stability, which is a critical aspect in meeting the increasing needs of our worldwide client base.
Mr. Stallings received his BA from Stanford University and an MBA from the Amos Tuck School at Dartmouth College. He is a CFA charterholder.
Agere is a leading CDMO focused on improving the oral bioavailability of insoluble active pharmaceutical ingredients (APIs). The company supports clients from screening to identify the optimal solubilization technology, through formulation design and development into cGMP manufacturing for Phase I through Phase IIb clinical trials. All services follow QbD guidelines, and are delivered on a fee-for-service basis. Agere's proprietary formulation design platform, Quadrant 2 , enables the company to deliver a customized solution for every compound to serve each individual client's requirements. The company is located in Bend, OR. For information about Agere or Mr. Stallings: www.agerepharma.com.
Agere Pharmaceuticals and Quadrant 2 are trademarks owned by Agere Pharmaceuticals, Inc.
For a Complete Version of this BUSINESS WIRE Press Release